Download PDF
Thromb Haemost 1997; 78(01): 562-565
DOI: 10.1055/s-0038-1657589
New treatments of von Wiltebrand disease
Schattauer GmbH Stuttgart

von Willebrand Disease: From the Bedside to Therapy

Louis M Aledort
Mount Sinai School of Medicine, New York, NY, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Sadler JE, Gralnick HR. Commentary: a new classification for von Willebrand’s disease. Blood 1994; 84: 676-679
    PubMedGoogle Scholar
  • 2 Ruggeri ZM. Structure and function of von Willebrand factor: Relationship to von Willebrand’s disease. Mayo Clinic Proc 1991; 6: 847-861
    PubMedGoogle Scholar
  • 3 von Willebrand EA. Hereditär pseudohemofil. Finska Läkaresälls-kapets Handlingar 1926; 67 (02) 007-112
    PubMedGoogle Scholar
  • 4 Minot GR. A familial hemorrhagic condition associated with prolongation of the bleeding time. Am J.Med Sci 1928; 175: 301-306
    PubMedGoogle Scholar
  • 5 Alexander B, Goldstein R. Dual hemostatic defect in pseudohemophilia. J Clin Invest 1953; 32: 55 (abst)
    PubMedGoogle Scholar
  • 6 Schulman I, Smith CH, Erlandson M, Fort E, Lee RE. Vascular hemophilia. A familial hemorrhagic disease in males and females characterized by combined antihemophilic globulin deficiency and vascular abnormality. Pediatrics 1956; 18: 347-361
    PubMedGoogle Scholar
  • 7 Singer K, Romot B. Pseudohemophilia type B. Arch Int Med 1956; 97: 715-725
    CrossrefPubMedGoogle Scholar
  • 8 Nilsson IM. Nebenwirkungen von Arzneimitteln auf Blut und Knochenmark, International Symposion, Malmö-Schweden, 1956. F.K. Schauttauer, Stuttgart 1957; p. 246
    PubMedGoogle Scholar
  • 9 Nilsson IM, Blombäck M, von Francken I. On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med Scand 1957; 159: 35-57
    CrossrefPubMedGoogle Scholar
  • 10 Nilsson IM, Blombäck M, Jorpes E, Blombäck B, Johansson S-A. von Willebrand’s disease and its correction with human plasma Fraction I-O. Acta Med Scand 1957; 159: 179-188
    PubMedGoogle Scholar
  • 11 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Arkiv Kemi 1956; 10: 415-443
    PubMedGoogle Scholar
  • 12 Nilsson EM, Blombäck M, Blombäck B. von Willebrand’s disease in Sweden: Its pathogenesis and treatment. Acta Med. Scand 1959; 164: 263-278
    PubMedGoogle Scholar
  • 13 Borchgrevink Chr F. Platelet adhesion in vivo in patients with bleeding disorders. Act Med Scand 1961; 170: 231-243
    PubMedGoogle Scholar
  • 14 Helium AJ. The adhesiveness of human blood platelets in vitro. Scand J Clin Lab Invest Supp 1960; 51: 001-110
    PubMedGoogle Scholar
  • 15 Cronberg S, Nilsson IM, Silwer J. Studies on the platelet adhesiveness in von Willebrand’s disease. Acta Med Scand 1966; 180: 43-54
    PubMedGoogle Scholar
  • 16 Salzman EW. Measurement of platelet adhesiveness. A simple in vitro technique demonstrating an abnormality in von Willebrand’s disease. J Lab Clin Med 1963; 62: 724-735
    PubMedGoogle Scholar
  • 17 Fressinaud E, Meyer D. von Willebrand disease in 1996. Haemophilia 1996; 2 (Suppl. 01) 09 (abstract)
    PubMedGoogle Scholar
  • 18 Bennett E, Dormandy K. Pool’s cryoprecipitate and exhausted plasma in the treatment of von Willebrand’s disease and factor-XI deficiency. Lancet 1966; 2: 731-732
    PubMedGoogle Scholar
  • 19 Silwer J. von Willebrand’s disease in Sweden. Acta Pediat Scand Supp 1973; 238: 005-154
    PubMedGoogle Scholar
  • 20 Perkins HA. Correction of the hemostatic defects in von Willebrand’s disease. Blood 1967; 30: 375-380
    PubMedGoogle Scholar
  • 21 Zimmerman TS, Ratnoff OD, Powell AE. Immunogic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand’s disease. J Clin Invest 1971; 50: 244-254
    CrossrefPubMedGoogle Scholar
  • 22 Howard MA, Firkin BG. Ristocetin — a new tool in the investigation of platelet aggregation. Thromb Diath Hemorrh 1971; 26: 262-269
    PubMedGoogle Scholar
  • 23 Bennett B, Ratnoff OD, Levin J. Immunologic studies in von Willebrand’s disease. Evidence that the antihemophilic factor (AHF) produced after infusion lacks an antigen associated with normal AHF and the inactive material produced by patients with classical hemophilia. J Clin Invest 1972; 51: 2597-2601
    CrossrefPubMedGoogle Scholar
  • 24 Weiss HJ, Hoyer LW. von Willebrand factor: Dissociation from anti-hemophilic factor procoagulant activity. Science 1973; 182: 1149-1151
    CrossrefPubMedGoogle Scholar
  • 25 van Mourik JA, Bouma BN, La Bruyère WT, de Graaf S, Mochtar IA. Factor VIII, a series of homologous oligomers and a complex of two proteins. Thromb Res 1974; 4: 155-164
    CrossrefPubMedGoogle Scholar
  • 26 Hoyer LW. The factor VIII complex: Structure and function. Blood 1981; 58: 01-13
    PubMedGoogle Scholar
  • 27 Blatt PM, Brinkhous KM, Culp HR, Krauss JS, Roberts HR. Antihemophilic factor concentrate therapy in von Willebrand disease. JAMA 1976; 236: 2770-2772
    CrossrefPubMedGoogle Scholar
  • 28 Mannucci PM, Moia M, Rebulla P, Altieri D, Monteagudo J, Castillo R. Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor. Am J Hemat 1987; 25: 55-65
    CrossrefPubMedGoogle Scholar
  • 29 Berntorp E, Nilsson IM. Use of a high purity factor VIII concentrate (Hemate P) in von Willebrand’s disease. Vox Sang 1989; 56: 212-217
    PubMedGoogle Scholar
  • 30 Holmberg L, Nilsson IM. von Willebrand’s disease. Eur J Haematol 1992; 48: 127-141
    PubMedGoogle Scholar
  • 31 Foster PA. A perspective on the use of factor VIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand’s disease unresponsive to DDAVP: Results of an international study. Thromb Haemost 1995; 74: 1370-1378
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 van Genderen PJJ, Michiels JJ, Bakker JS, van’t Veer MB. Effectiveness of high dose intravenous gamma globulin therapy in acquired von Willebrand’s disease. Vox Sang 1994; 67: 14-17
    CrossrefPubMedGoogle Scholar
  • 33 Mannucci PM, Ruggeri ZM, Paroti CapitanoA. l-Desamino-8-darginine vasopressin; a new pharmacological approach to the management of hemophilia and von Willebrand’s disease. Lancet 1977; 1: 869-872
    PubMedGoogle Scholar
  • 34 Lethagen S, Harris AS, Nilsson IM. Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand’s disease type I. Blut 1991; 60: 187-191
    PubMedGoogle Scholar
  • 35 Rose E, Aledort LM. Nasal Spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand’s disease. Ann Int Med 1991; 114: 563-568
    CrossrefPubMedGoogle Scholar
  • 36 Seremetis SV, Rose EH, Forster A, Maksoud J, Aledort LM. High concentration desmopressin nasal spray: a simple, effective, and convenient treatment for mild hemophilia A and type I von Willebrand disease in home care and surgical settings. Ann Int Mwd accepted for publication.
    PubMedGoogle Scholar